Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618015 | 0.96 | TLR7 (0.55) | TLR7TSHRTLR8LMNAMAPT | |
| SCHEMBL10123169 | 0.93 | TLR7 (0.50) | TLR7TSHRTLR8LMNAMAPT | |
| SCHEMBL3178411 | 0.91 | TLR7 (0.60) | TLR7TLR8LMNAALDH1A1MEN1 | |
| SCHEMBL6106242 | 0.88 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL5349914 | 0.88 | TLR7 (0.47) | TLR7TLR8LMNAMAPTHPGD | |
| SCHEMBL3968315 | 0.87 | TLR7 (0.59) | TLR7TLR8LMNAMAPTHPGD | |
| SCHEMBL5354895 | 0.87 | TLR7 (0.47) | TLR7TLR8LMNAMAPTHPGD | |
| SCHEMBL4307950 | 0.86 | TLR7 (0.49) | TLR7TSHRTLR8MAPTALDH1A1 | |
| SCHEMBL5617844 | 0.86 | TLR7 (0.45) | TLR7TSHRTLR8LMNAMAPT | |
| SCHEMBL5617119 | 0.86 | TLR7 (0.45) | TLR7TLR8LMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673932-B2 | Oxime substituted imidazo-containing compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-7648997-B2 | Immunomodulators for inducing cytokine biosynthesis, for treatment of diseases including viral and neoplastic diseases; 1-[3-(Aminooxy)propyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine; N-[3-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propoxy]cyclopropanecarboxamide | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1653955-A4 | HYDROXYLAMINE SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1653914-A4 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080114019-A1 | Hydroxylamine Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
| EP-1653914-A2 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1653955-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005018551-A2 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018556-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114019-A1 | Hydroxylamine Substituted Imidazoquinolines | IFNG, IRF3, IL2 | TLR7 93/4885TSHR 2239/4885TLR8 177/4885 |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 69/4885TSHR 1047/4885TLR8 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.